Literature DB >> 21284992

HIV reservoirs and latency models.

Matthew J Pace1, Luis Agosto, Erin H Graf, Una O'Doherty.   

Abstract

The main impediment to a cure for HIV is the existence of long-lasting treatment resistant viral reservoirs. In this review, we discuss what is currently known about reservoirs, including their formation and maintenance, while focusing on latently infected CD4+ T cells. In addition, we compare several different in vivo and in vitro models of latency. We comment on how each model may reflect the properties of reservoirs in vivo, especially with regard to cell phenotype, since recent studies demonstrate that multiple CD4+ T cell subsets contribute to HIV reservoirs and that with HAART and disease progression the relative contribution of different subsets may change. Finally, we focus on the direct infection of resting CD4+ T cells as a source of reservoir formation and as a model of latency, since recent results help explain the misconception that resting CD4+ T cells appeared to be resistant to HIV in vitro.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21284992      PMCID: PMC3618966          DOI: 10.1016/j.virol.2010.12.041

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  163 in total

1.  Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States.

Authors:  Kathleen McDavid Harrison; Ruiguang Song; Xinjian Zhang
Journal:  J Acquir Immune Defic Syndr       Date:  2010-01       Impact factor: 3.731

Review 2.  HIV reservoirs, latency, and reactivation: prospects for eradication.

Authors:  Viktor Dahl; Lina Josefsson; Sarah Palmer
Journal:  Antiviral Res       Date:  2009-10-04       Impact factor: 5.970

Review 3.  Elucidating the elite: mechanisms of control in HIV-1 infection.

Authors:  Karen A O'Connell; Justin R Bailey; Joel N Blankson
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

Review 4.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.

Authors:  Mayte Coiras; María Rosa López-Huertas; Mayte Pérez-Olmeda; José Alcamí
Journal:  Nat Rev Microbiol       Date:  2009-11       Impact factor: 60.633

5.  No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

Authors:  Rajesh T Gandhi; Ronald J Bosch; Evgenia Aga; Mary Albrecht; Lisa M Demeter; Carrie Dykes; Barbara Bastow; Michael Para; Jun Lai; Robert F Siliciano; Janet D Siliciano; Joseph J Eron
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

Review 6.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

7.  Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year.

Authors:  Bradford K Berges; Sarah R Akkina; Leila Remling; Ramesh Akkina
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

8.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

9.  The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells.

Authors:  Dongyang Yu; Weifeng Wang; Alyson Yoder; Mark Spear; Yuntao Wu
Journal:  PLoS Pathog       Date:  2009-10-23       Impact factor: 6.823

10.  Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

Authors:  Alexander O Pasternak; Suzanne Jurriaans; Margreet Bakker; Jan M Prins; Ben Berkhout; Vladimir V Lukashov
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

View more
  58 in total

Review 1.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

Review 2.  Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Authors:  Maxime J Jean; Guillaume Fiches; Tsuyoshi Hayashi; Jian Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-12       Impact factor: 2.205

Review 3.  Barriers for HIV Cure: The Latent Reservoir.

Authors:  Sergio Castro-Gonzalez; Marta Colomer-Lluch; Ruth Serra-Moreno
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-28       Impact factor: 2.205

4.  A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection.

Authors:  Matthew S Dahabieh; Marcel Ooms; Viviana Simon; Ivan Sadowski
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

5.  Entry of HIV in primary human resting CD4(+) T cells pretreated with the chemokine CCL19.

Authors:  Jenny L Anderson; Karey Cheong; Amas K H Lee; Suha Saleh; Candida da Fonseca Pereira; Paul U Cameron; Sharon R Lewin
Journal:  AIDS Res Hum Retroviruses       Date:  2014-03       Impact factor: 2.205

6.  Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.

Authors:  Jie Lan; Kai Yang; Daniel Byrd; Ningjie Hu; Tohti Amet; Nicole Shepherd; Mona Desai; Jimin Gao; Samir Gupta; Yongtao Sun; Qigui Yu
Journal:  J Immunol       Date:  2014-08-22       Impact factor: 5.422

7.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

8.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

9.  Dilazep synergistically reactivates latent HIV-1 in latently infected cells.

Authors:  Hanxian Zeng; Sijie Liu; Pengfei Wang; Xiying Qu; Haiyan Ji; Xiaohui Wang; Xiaoli Zhu; Zhishuo Song; Xinyi Yang; Zhongjun Ma; Huanzhang Zhu
Journal:  Mol Biol Rep       Date:  2014-08-05       Impact factor: 2.316

10.  Peripheral immunophenotype and viral promoter variants during the asymptomatic phase of feline immunodeficiency virus infection.

Authors:  B Murphy; C Hillman; S McDonnel
Journal:  Virus Res       Date:  2013-11-28       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.